Bone Health Technologies (BHT) today announced the company has been awarded a fifth patent for Osteoboost—the first and only FDA-cleared prescription medical device to treat osteopenia…
Bone Health Technologies today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for OsteoboostTM, the first non-pharmacological device-based prescription treatment for postmenopausal women diagnosed with osteopenia…
Bone Health Technologies (BHT) has been granted its fourth patent to further its commercialization of the Osteoboost device.
Redwood City, CA (SEPTEMBER 20TH, 2023) – Bone Health Technologies (BHT), a leader in developing technologies for improving bone health and preventing bone diseases, announces the appointment of two new board directors: Jeani Delagardelle and Eric Meyer. Onboarding these two expert thought leaders will aid in progressing BHT’s development, research,…
Read more
Per Protocol Participants saw an 85% Reduction in the Loss of Vertebral Bone Density in One Year Chicago, IL (June 16, 2023)– Bone Health Technologies (BHT), a pioneer in health technologies for preventing and treating bone health diseases, is presenting pivotal trial data for Osteoboost, a novel treatment for low…
Read more
